Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma
Al-Batran, S., Wainberg, Z., Muro, K., Molena, D., Van Cutsem, E., Hyung, W.,…Tabernero, J., Janjigian, Y. (2025). Event-free survival (EFS) … Read More
